WO1991014456A3 - Improved compositions for photodynamic therapy - Google Patents
Improved compositions for photodynamic therapy Download PDFInfo
- Publication number
- WO1991014456A3 WO1991014456A3 PCT/CA1991/000093 CA9100093W WO9114456A3 WO 1991014456 A3 WO1991014456 A3 WO 1991014456A3 CA 9100093 W CA9100093 W CA 9100093W WO 9114456 A3 WO9114456 A3 WO 9114456A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- photosensitizer
- photodynamic therapy
- conjugation
- specific component
- target specific
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002428 photodynamic therapy Methods 0.000 title abstract 2
- 239000003504 photosensitizing agent Substances 0.000 abstract 5
- 230000021615 conjugation Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 1
- 230000002165 photosensitisation Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/498,042 US5053423A (en) | 1990-03-22 | 1990-03-22 | Compositions for photodynamic therapy |
US498,042 | 1990-03-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1991014456A2 WO1991014456A2 (en) | 1991-10-03 |
WO1991014456A3 true WO1991014456A3 (en) | 1991-12-12 |
Family
ID=23979389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1991/000093 WO1991014456A2 (en) | 1990-03-22 | 1991-03-22 | Improved compositions for photodynamic therapy |
Country Status (3)
Country | Link |
---|---|
US (1) | US5053423A (en) |
AU (1) | AU7474791A (en) |
WO (1) | WO1991014456A2 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1039283C (en) * | 1988-12-12 | 1998-07-29 | Fmc公司 | Prodn. and use of porphyrins |
US5238940A (en) * | 1990-03-22 | 1993-08-24 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
US6187572B1 (en) | 1990-04-16 | 2001-02-13 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants |
US5798238A (en) * | 1990-04-16 | 1998-08-25 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer |
US5418130A (en) * | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
US5641878A (en) * | 1991-05-15 | 1997-06-24 | Diatron Corporation | Porphyrin, azaporphyrin, and related fluorescent dyes free of aggregation and serum binding |
US5880287A (en) * | 1990-05-15 | 1999-03-09 | Hyperion, Inc. | Polyoxyhydrocarbyl related products and methods for fluorescence assays |
WO1991018006A1 (en) * | 1990-05-15 | 1991-11-28 | Diatron Corporation | Fluorescent porphyrin, and fluorescent phthalocyanine - polyethylene glycol, polyol, and saccharide derivatives as fluorescent probes |
US6060598A (en) * | 1990-05-15 | 2000-05-09 | Hyperion, Inc. | Fluorescence immunoassays using fluorescent dyes free of aggregation and serum binding |
US5919922A (en) * | 1990-05-15 | 1999-07-06 | Hyperion, Inc. | Fluorescent dyes free of aggregation and serum binding |
US5622685A (en) * | 1990-05-30 | 1997-04-22 | Deutches Krebsforchunszentrum Stiftung Des Offentlichen Rechts | Polyether-substituted porphyrin anti-tumor agents |
CA2047969A1 (en) * | 1990-08-17 | 1992-02-18 | Thomas D. Madden | Benzoporphyrin vesicles |
US5169944A (en) * | 1991-04-12 | 1992-12-08 | Board Of Regents Of The University Of Washington | Methods and compositions for the enteral administration of hepatobiliary MRI contrast agents |
IL104734A0 (en) * | 1993-02-15 | 1993-06-10 | Univ Bar Ilan | Bioactive conjugates of cellulose with amino compounds |
US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
KR100361933B1 (en) | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | Chemically defined nonpolymeric bonds form the platform molecule and its conjugate |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US6992107B1 (en) * | 1995-03-10 | 2006-01-31 | Photocure Asa | Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy |
US5707608A (en) * | 1995-08-02 | 1998-01-13 | Qlt Phototherapeutics, Inc. | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer |
US5834503A (en) * | 1996-06-14 | 1998-11-10 | Qlt Phototherapeutics, Inc. | Methods to treat arterial plaque |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
WO2000012512A1 (en) | 1998-08-28 | 2000-03-09 | Destiny Pharma Limited | Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them |
US6458953B1 (en) * | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
CN1434726A (en) | 2000-06-08 | 2003-08-06 | 拉卓拉药物公司 | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
GB0018527D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Composition |
US7175611B2 (en) | 2002-06-05 | 2007-02-13 | Mark Alan Mitchnick | Antimicrobial release system |
ATE292144T1 (en) | 2002-08-02 | 2005-04-15 | Inst Curie | SHIGA TOXIN SUBUNIT B AS A VECTOR FOR DIAGNOSIS OF TUMORS AND FOR DRUG ADMINISTRATION TO GB3-EXPRESSING TUMORS |
US20060231107A1 (en) * | 2003-03-07 | 2006-10-19 | Glickman Randolph D | Antibody-targeted photodynamic therapy |
AU2004297228A1 (en) | 2003-12-03 | 2005-06-23 | Nektar Therapeutics Al, Corporation | Method of preparing maleimide functionalized polymers |
US7985418B2 (en) * | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
JP2008526771A (en) * | 2004-12-30 | 2008-07-24 | ジェンザイム コーポレーション | Zinc-containing treatment for hyperphosphatemia |
US20060223750A1 (en) * | 2005-04-01 | 2006-10-05 | Allergan, Inc. | Agents and methods for enhancing photodynamic therapy |
CN101268118B (en) | 2005-07-19 | 2012-09-19 | 尼克塔治疗公司 | Method for preparing polymer maleimides |
EP1951266A2 (en) | 2005-09-02 | 2008-08-06 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
WO2007035313A2 (en) | 2005-09-15 | 2007-03-29 | Genzyme Corporation | Sachet formulation for amine polymers |
AR060690A1 (en) * | 2005-11-08 | 2008-07-10 | Genzyme Corp | POLYMERS CONTAINING MAGNESIUM FOR HYPERPHOSPHATEMIA |
US20100135950A1 (en) * | 2006-07-05 | 2010-06-03 | Genzyme Corporation | Iron(II)-Containing Treatments for Hyperphosphatemia |
US8556950B2 (en) | 2006-08-24 | 2013-10-15 | Boston Scientific Scimed, Inc. | Sterilizable indwelling catheters |
ATE454146T1 (en) * | 2006-08-29 | 2010-01-15 | Stichting Tech Wetenschapp | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MYCOTIC SKIN DISEASES AND METHOD FOR THE PRODUCTION THEREOF |
KR101035269B1 (en) * | 2007-04-23 | 2011-05-26 | 한국과학기술연구원 | Novel photosensitizer based on pholymer derivatives-photosensitizer conjugates for photodynamic therapy |
EP2113257A1 (en) * | 2008-04-30 | 2009-11-04 | Consorzio per il Centro di Biomedica Moleculare Scrl | Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer |
SG11201405553YA (en) | 2012-03-08 | 2014-11-27 | Halozyme Inc | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
KR101419254B1 (en) | 2012-10-15 | 2014-07-17 | 국립암센터 | Enzyme-responsive graphene oxide/biopolymer-photosensitizer nanocomplex and composition for fluorescence image and photodynamic/photothermal treatment comprising thereof |
KR20160055253A (en) | 2013-09-12 | 2016-05-17 | 할로자임, 아이엔씨 | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
US20150122738A1 (en) * | 2013-11-05 | 2015-05-07 | Angelo Gaitas | Blood Cleansing System & Method |
US10166321B2 (en) | 2014-01-09 | 2019-01-01 | Angiodynamics, Inc. | High-flow port and infusion needle systems |
MA41202A (en) | 2014-12-18 | 2017-10-24 | Genzyme Corp | CROSS-LINKED POLYDIALLYMINE COPOLYMERS FOR THE TREATMENT OF TYPE 2 DIABETES |
WO2017031084A1 (en) * | 2015-08-14 | 2017-02-23 | The Regents Of The University Of California | Poly(vinyl alcohol) nanocarriers |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
US20210070845A1 (en) | 2017-12-15 | 2021-03-11 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0161606A2 (en) * | 1982-09-27 | 1985-11-21 | Health Research, Inc. | Drug, and methods of preparing and using it for treatment of tumors |
EP0276121A2 (en) * | 1987-01-20 | 1988-07-27 | The University Of British Columbia | Wavelength-specific cytotoxic agents |
WO1990002747A1 (en) * | 1988-09-08 | 1990-03-22 | Ultra Diagnostics Corporation | Red-shifted phthalocyanine and tetrabenztriazaporphyrin reagents |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4268947A (en) * | 1977-08-29 | 1981-05-26 | Carrier Corporation | Method of securing a capillary tube passing through a wall |
US4500507A (en) * | 1981-10-30 | 1985-02-19 | Wong Dennis W | Diagnostic composition for radiologic imaging of neoplasms in the body and method of preparation |
US4577636A (en) * | 1982-11-23 | 1986-03-25 | The Beth Israel Hospital Association | Method for diagnosis of atherosclerosis |
US4512762A (en) * | 1982-11-23 | 1985-04-23 | The Beth Israel Hospital Association | Method of treatment of atherosclerosis and a balloon catheter for same |
US4748120A (en) * | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
US4727027A (en) * | 1983-05-02 | 1988-02-23 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
US4485806A (en) * | 1983-10-24 | 1984-12-04 | Calspan Corporation | Method and apparatus for evacuating contaminated casualties |
US4675338A (en) * | 1984-07-18 | 1987-06-23 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
US4753958A (en) * | 1985-02-07 | 1988-06-28 | University Of Cal | Photochemotherapy of epithelial diseases with derivatives of hematoporphyrins |
US4920143A (en) * | 1987-04-23 | 1990-04-24 | University Of British Columbia | Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents |
-
1990
- 1990-03-22 US US07/498,042 patent/US5053423A/en not_active Expired - Fee Related
-
1991
- 1991-03-22 WO PCT/CA1991/000093 patent/WO1991014456A2/en unknown
- 1991-03-22 AU AU74747/91A patent/AU7474791A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0161606A2 (en) * | 1982-09-27 | 1985-11-21 | Health Research, Inc. | Drug, and methods of preparing and using it for treatment of tumors |
EP0276121A2 (en) * | 1987-01-20 | 1988-07-27 | The University Of British Columbia | Wavelength-specific cytotoxic agents |
WO1990002747A1 (en) * | 1988-09-08 | 1990-03-22 | Ultra Diagnostics Corporation | Red-shifted phthalocyanine and tetrabenztriazaporphyrin reagents |
Non-Patent Citations (4)
Title |
---|
Biochimica et Biophysica Acta, vol. 932, 1988, Elsevier Science Publishers B.V., (Amsterdam, NL), I. Inamura et al.: "Properties of the water-soluble chlorophyll-synthetic linear macromolecular complexes", pages 335-344, see page 335, abstract * |
J. Chem. Soc., Chem. Commun., 1984, (London, GB), A.R. Morgan et al.: "Ready syntheses of benzoporphyrins via Diels-Alder reactions with protoporphyrin IX", pages 1047-1048, see the whole article (cited in the application) * |
Proc. Natl. Acad. Sci. USA, vol. 83, November 1986, (Washington, DC, US), A.R. Oseroff et al.: "Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates", page 8744-8748, see page 8744, abstract; page 8744, paragraph 8 - page 8745, paragraph 2; page 8746, table 1; page 8747, paragraphs 3,4 (cited in the application) * |
Proc. SPIE - Int. Soc. Opt. Eng., Advances in Photochemotherapy, vol. 997, 1988, (Bellingham, Washington, US), N.L. Krinick et al.: "Targetable photo-activatable drugs. 1. Synthesis of water-soluble galactosamine containing polymeric carriers of chlorin e6 and their photodynamic effect on PLC cells in vitro", pages 70-83 * |
Also Published As
Publication number | Publication date |
---|---|
WO1991014456A2 (en) | 1991-10-03 |
US5053423A (en) | 1991-10-01 |
AU7474791A (en) | 1991-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991014456A3 (en) | Improved compositions for photodynamic therapy | |
EP1698629A3 (en) | Polyamines and their use in therapy | |
LU92099I2 (en) | Golimumab and its pharmaceutically acceptable derivatives (SIMPONI®) | |
HU9402142D0 (en) | Pharmaceutical composition for treating tumors | |
WO1997029779A3 (en) | EGF-Genistein conjugates for the treatment of cancer | |
UA103758C2 (en) | Insulin-oligomer conjugates, formulations and uses thereof | |
WO2003022210A3 (en) | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith | |
WO2001062300A3 (en) | Caspase activated prodrugs therapy | |
CA2406650A1 (en) | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites | |
AU2582488A (en) | Drug-monoclonal antibody conjugates | |
HUP0300421A2 (en) | Method of treatment using ligand-immunogen conjugates | |
BG105810A (en) | Camptothecin derivatives having antitumor activity | |
CA2015060A1 (en) | Novel antibody delivery system for biological response modifiers | |
CA2274074A1 (en) | Novel compounds with analgesic effect | |
CA2124218A1 (en) | Cytotoxic drug therapy | |
CA2005880A1 (en) | Macrocyclic aminophosphonic acid complexes, their preparation formulations and use | |
EP1007082A4 (en) | Modified tumor necrosis factor | |
CA2153775A1 (en) | Potentiation of Temozolomide in Human Tumour Cells | |
AU669122B2 (en) | New pyrazine derivatives, their preparation and their use | |
WO2001026704A3 (en) | Targeted drug activation | |
CA2221900A1 (en) | Use of trospium chloride and 2-component system for the same | |
GB2013084A (en) | Ophthalmic compositions | |
NO912864L (en) | LOCATION SPECIFIC IN VIVO ACTIVATION OF THERAPEUTIC RELATIONS | |
CA2095352A1 (en) | Compositions containing psyllium | |
EP1023901A4 (en) | Ameliorant for hepatitis c remedial effect and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO PL RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO PL RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |